If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Why fret over the next market crash? These three stocks should be able to keep raising the payouts they send you each quarter.
Has the market beaten this healthcare stock into bargain territory?
Success for Sage Therapeutics' postpartum depression drug bodes well for a related candidate from Marinus Pharmaceuticals.
Keytruda just wasn't strong enough to overcome stiff headwinds that made Merck's third-quarter report one investors would like to forget.
It doesn't take much to drag down the stock price of a biotech as richly valued as this one.
A Swiss healthcare giant made an attractive offer for the radioactive imaging product manufacturer.
Tiny start-up AnaptysBio helped spread fear that Dupixent's ongoing commercial launch might fizzle out.
One of the company's biggest clients just became a major threat in 11 states.
Impressive pivotal trial results suggest an application for the company's troubled candidate is headed to the FDA.
Investors were pleased to see the company take a big step towards commercializing its most important asset.
Despite some bright points, a revenue miss and contracting margins in the company's third-quarter report are taking a toll.
Find out why investors throw all caution to the wind when it comes to this stock.
This company's CAR-T and sickle-cell disease programs are turning heads.
Despite some positive news, a shocking lack of visibility spooked the market.
Long-awaited trial results point in the right direction for Alnylam and suggest tougher competition for Ionis.
A renter in arrears spooked investors into selling shares of this healthcare REIT.
These three biotech stocks helped a lot of investors get rich this year. Are there more gains ahead?
Another strong earnings report suggests this company's growth story isn't over yet.
The spinal surgery underdog posted some impressive growth abroad.